Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
Allakos Inc (ALLK) is a clinical-stage biotechnology company pioneering antibody therapies targeting immune receptors to treat mast cell-related diseases. This dedicated news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about AK006 clinical trials, partnership agreements, and scientific advancements in immunomodulation. Our curated collection features official press releases, trial result disclosures, and strategic updates directly from Allakos, ensuring you receive unfiltered insights into their Siglec-6 targeting therapies.
Bookmark this page for centralized access to critical updates about Allakos' research programs, including developments in treating chronic urticaria, asthma, and gastrointestinal disorders. Check regularly for new information on therapeutic candidate progress, patent filings, and peer-reviewed study publications that may impact investment decisions.
Allakos Inc. (Nasdaq: ALLK) provided a business update on March 6, 2023, reporting financial results for Q4 and full year 2022. Key developments include the initiation of a Phase 2b study of lirentelimab for chronic spontaneous urticaria and continued enrollment for atopic dermatitis. The company reported Q4 2022 research and development expenses of $35.4 million, down from $72.9 million in Q4 2021, attributed to cost-cutting measures. General and administrative expenses also decreased to $10.8 million from $23.2 million. The net loss shrank to $43.0 million from $94.4 million year-over-year, and cash reserves stood at $279.8 million.
FAQ
What is the current stock price of Allakos (ALLK)?
What is the market cap of Allakos (ALLK)?
